沙格列汀联合门冬胰岛素30治疗超重2型糖尿病患者的疗效分析

Efficacy Analysis of Saxagliptin Combined with Insulin Aspart 30 in the Treatment of Overweight Patients with Type 2 Diabetes

目的研讨超重2型糖尿病患者采用沙格列汀与门冬胰岛素30共同治疗的临床价值。方法选取白银市康复医院2016年6月至2020年1月收诊的超重[体质量指数(BMI)≥25 kg/m2]2型糖尿病患者100例,按照随机数字表法分为观察组(50例)与对照组(50例)。对照组给予门冬胰岛素30单药治疗,观察组基于对照组条件配合沙格列汀用药,疗程(24周)结束后,对比两组的每日胰岛素用量、胰岛功能以及血糖水平。结果治疗后,观察组每日胰岛素用量少于对照组(P<0.05)。治疗后,观察组的胰岛功能指标胰岛素抵抗指数(HOMA-IR)与计算胰岛素分泌指数(HOMA-β)均优于对照组(P<0.05)。治疗后,观察组血糖指标餐后2 h血糖(2 hPBG)、糖化血红蛋白(HbAlc)均低于对照组(P<0.05)。结论对超重2型糖尿病患者联合应用沙格列汀与门冬胰岛素30治疗,能够在有效控制胰岛素用量的同时,明显降低患者的血糖水平,改善其胰岛功能。

Objective To investigate the clinical value of combination therapy of saxagliptin and insulin aspart 30 in overweight patients with type 2 diabetes mellitus.Methods From June 2016 to January 2020 in Baiyin Rehabilitation Hospital,100 patients with overweight[body mass index(BMI)≥25 kg/m2]with type 2 diabetes were selected and randomly divided into observation group(50 cases)and control group(50 cases),50 cases in each group.The control group was given insulin aspart 30 single drug treatment,and the observation group was given saxagliptin based on the conditions of the control group.After the course of treatment(24 weeks),the daily insulin dosage,islet function and blood glucose level of the two groups were compared.Results The daily insulin consumption in the observation group was less than that in the control group(P<0.05).After treatment,the islet function indexes(HOMA-IR and HOMA-β)of the observation group were better than those of the control group(P<0.05).After treatment,the blood glucose indexes(2 hPBG,HbAlc)in the observation group were lower than those in the control group(P<0.05).Conclusion The combination of saxagliptin and insulin aspart 30 in the treatment of overweight type 2 diabetes mellitus can effectively control the insulin dosage,significantly reduce the blood glucose level and improve the islet function.